In vitro metastatic assays showed that activation of the MAPK/JNK signalling by JNK agonist (Anisomycin) partly recovered CRC cell mobility and upregulated UCA1 expression in Sec62‐silencing cells. Here, SEC62 is linked to colorectal carcinoma.